Please use this identifier to cite or link to this item:
|Title:||Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease|
|Authors:||Oliveira, Fabricio Ferreira de [UNIFESP]|
Bertolucci, Paulo Henrique Ferreira [UNIFESP]
Chen, Elizabeth Suchi [UNIFESP]
Smith, Marilia de Arruda Cardoso [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
|Citation:||Journal of the Neurological Sciences. Amsterdam: Elsevier B.V., v. 336, n. 1-2, p. 103-108, 2014.|
|Abstract:||To evaluate correlations of pharmacological treatment with cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease with low schooling, subjects were assessed for demographic features, neuropsychiatric symptoms, cognitive decline, functionality, caregiver burden, APOE haplotypes and pharmacological treatment. Among 217 patients, use of cholinesterase inhibitors with or without Memantine was associated with less neuropsychiatric symptoms, while anti-psychotics and/or antiepileptic drugs were associated with lower instrumental functionality. Anti-psychotics were also associated with more neuropsychiatric symptoms in moderately impaired patients, possibly reflecting the greater need for such treatment when behavioral symptoms are present. Patients receiving more medications were usually younger, obese, married, with higher schooling and more neuropsychiatric symptoms. APOE4+ haplotypes were correlated with earlier dementia onset, but not with pharmacological treatment. Higher caregiver burden was associated with more psychotropic drugs. A trend was found for treatment with cholinesterase inhibitors and Memantine to be associated with longer lengths of dementia for moderately impaired but not for severely impaired patients, regardless of APOE haplotypes, translating into a synergistic effect among such medications for slowing cognitive decline but not for prolonging survival. Further longitudinal studies may be required to assess dose-response relationships regarding treatment with psychotropics for patients with dementia. (C) 2013 Elsevier B.V. All rights reserved.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.